Free Trial

Benitec Biopharma (NASDAQ:BNTC) Stock Price Expected to Rise, Wedbush Analyst Says

Benitec Biopharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wedbush raised its price target on Benitec Biopharma to $20 from $17 and maintained an “outperform” rating, implying 121% upside from the stock’s current price.
  • Analyst sentiment is generally positive: MarketBeat reports a “Moderate Buy” consensus and an average target price of $22.75, based on seven Buy, one Hold, and one Sell rating.
  • Benitec reported a quarterly loss of $0.26 per share, beating analyst estimates of a $0.28 loss by $0.02.
  • MarketBeat previews the top five stocks to own by December 1st.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) had its target price raised by research analysts at Wedbush from $17.00 to $20.00 in a report released on Monday, Benzinga reports. The brokerage presently has an "outperform" rating on the biotechnology company's stock. Wedbush's target price would indicate a potential upside of 121.24% from the stock's current price.

BNTC has been the subject of several other reports. HC Wainwright restated a "buy" rating on shares of Benitec Biopharma in a research report on Monday, November 2nd. Citigroup reiterated a "market outperform" rating on shares of Benitec Biopharma in a report on Tuesday, October 6th. Wall Street Zen cut Benitec Biopharma from a "hold" rating to a "sell" rating in a report on Saturday, September 19th. Royal Bank Of Canada raised Benitec Biopharma to an "outperform" rating in a research report on Tuesday, September 15th. Finally, Raymond James Financial initiated coverage on Benitec Biopharma in a report on Friday, October 23rd. They issued an "outperform" rating and a $14.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $22.75.

Check Out Our Latest Analysis on Benitec Biopharma

Benitec Biopharma Stock Performance

Shares of BNTC opened at $9.04 on Monday. The stock has a market cap of $315.41 million, a P/E ratio of -8.86 and a beta of 0.26. The company has a 50-day moving average of $9.67 and a two-hundred day moving average of $11.39. Benitec Biopharma has a 12-month low of $7.89 and a 12-month high of $14.39.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02. As a group, analysts forecast that Benitec Biopharma will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Benitec Biopharma

A number of institutional investors have recently bought and sold shares of the stock. AWM Investment Company Inc. purchased a new stake in shares of Benitec Biopharma during the 2nd quarter valued at $2,515,000. Bank of New York Mellon Corp purchased a new position in shares of Benitec Biopharma in the 2nd quarter worth $804,000. Nantahala Capital Management LLC boosted its holdings in Benitec Biopharma by 12.7% in the third quarter. Nantahala Capital Management LLC now owns 1,677,567 shares of the biotechnology company's stock valued at $16,776,000 after acquiring an additional 189,196 shares during the last quarter. Bank of America Corp DE boosted its holdings in Benitec Biopharma by 43.3% in the first quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company's stock valued at $185,000 after acquiring an additional 5,251 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Benitec Biopharma by 18.7% in the second quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company's stock valued at $107,000 after acquiring an additional 1,256 shares during the last quarter. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

(Get Free Report)

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company's lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.

Further Reading

Analyst Recommendations for Benitec Biopharma (NASDAQ:BNTC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Benitec Biopharma Right Now?

Before you consider Benitec Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.

While Benitec Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines